Article

InnoCore, Allergan expand partnership

InnoCore Pharmaceuticals has signed an exclusive license and collaboration agreement with Allergan Inc.

 

Groningen, The Netherlands-InnoCore Pharmaceuticals has signed an exclusive license and collaboration agreement with Allergan Inc.

Under the agreement, the companies will expand their existing collaboration and jointly continue to develop long-acting ocular drug delivery products for the treatment of ophthalmic diseases.

Utilizing its patented SynBiosys polymeric drug delivery platform, InnoCore will formulate Allergan’s proprietary drugs into pharmaceutical products expected to be capable of sustained release for many months following a single ocular injection.

“We are very excited that we have expanded this important partnership with Allergan, a company that is widely recognized as a leading company in the development of controlled release ophthalmology medicines,” said Jan Hendriks, chief executive officer of InnoCore. “Expanding our partnership with Allergan is a great opportunity for us to further grow InnoCore in line with our ambitions.”

 

For more articles in this issue of Ophthalmology Times eReport, click here.

 

 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.